Patent AnalyticsExaminers
Rankings

Company or institution

TAKEDA PHARMACEUTICALS U.S.A., INC.

62 applicationsfiled 2006 to 2025

Allowance rate
61%
−14 pts vs the USPTO range 48% to 73%
Rejections before allowance
2.1
+0.5 vs the USPTO
Months to first action
14.5 mo
−4.1 vs the USPTO
Needed an RCE
54%
+26 pts vs the USPTO

Timeline

Applications by filing year: drag across the years to study a period

Allowed in green, abandoned in red, pending in grey. The figures above and the charts that can be recomputed by filing year follow the span you pick.

Compared with the office

Against every applicant before the USPTO

Unlock the comparison with the officeFree with an account. No card needed.

Create a free account

Trend

Allowance by filing year

Unlock the trendIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

Domains

Where the applications fall

CPC subclasses

A61K Medical preparations51 apps
C12N Microorganisms or enzymes7 apps
C07C 3 apps
C07D Heterocyclic compounds1 apps

Art units

162716 apps
16297 apps
16287 apps
16215 apps
16124 apps
OPAP4 apps

Who represents them

Law firms and agents on their applications

Bars show the share of decided applications that were allowed.

Unlock the firms on their applicationsIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

Rejection fingerprint

What gets rejected, by statute

Share of parsed office actions raising each ground; blue is the USPTO.

Unlock the rejection fingerprintIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

What works

Allowance by strategy used

Unlock what works for this filerIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in

Interviews

Does an interview help?

Unlock the interview figuresFree with an account. No card needed.

Create a free account

Applications

Every application in the record

ApplicationTitleFiledStatusRejectionsRCEsTo 1st action
19182285OLIGONUCLEOTIDES FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIA…2025-04-17Pending00n/a
19028246SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS2025-01-17Pending00n/a
18852084METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS2024-09-27Pending00n/a
15880386Method and apparatus for adaptive signal processing2012-01-10Allowed1012.0 mo
15677028Composition and method for controlled release2015-02-11Abandoned4123.0 mo
15337426Distributed ledger transaction verification2018-03-12Allowed3020.0 mo
15233150Thermal management of battery assemblies2021-04-13Pending2117.0 mo
15292552Machine learning model for anomaly detection2012-05-14Allowed1014.0 mo
15880471Wireless power transfer coil arrangement2015-06-15Abandoned4125.0 mo
15311917Catalyst for selective hydrogenation2018-07-16Allowed3022.0 mo
Unlock all 62 applications, each with its full timelineIncluded in Pro, from $29 a month. Cancel any time.

See plans Sign in